tirzepatide osa Medscape | The FDA approved Zepbound in December 2024 for the treatment of moderate-to-severe obstructive sleep apnea in patients with obesity after Antidiabetic Drug Tirzepatide Could Benefit

As healthcare professionals, understanding these pharmacological differences helps us make more informed, evidence-based decisions and optimize patient care

It works by stimulating GLP-1 production in the body, which helps the body produce more insulin when needed

Tirzepatide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

A complete protocol is 48 weeks of once-weekly injections with gradual dose escalation

President Obama announce shared vision for perimeter security and economic competitiveness between Canada and the United States" (Press release)